Related references
Note: Only part of the references are listed.Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Tineke Casneuf et al.
LEUKEMIA (2021)
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Saad Z Usmani et al.
Lancet Haematology (2020)
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
Suzanne Cole et al.
ARTHRITIS RESEARCH & THERAPY (2018)
PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety
Thomas S. Y. Chan et al.
ANNALS OF HEMATOLOGY (2018)
The diagnosis and management of NK/T-cell lymphomas
Eric Tse et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
X. S. Xu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase
Yok-Lam Kwong et al.
BLOOD (2017)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma
Parameswaran Hari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases
Bradley M. Haverkos et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)
Christopher Chiu et al.
BLOOD (2016)
CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type
Liang Wang et al.
ANNALS OF HEMATOLOGY (2015)
High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study
Hao Ding et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79
Jeroen Lammerts van Bueren et al.
BLOOD (2014)
First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma
Liang Wang et al.
CANCER (2013)
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma
Hee Kyung Ahn et al.
INVESTIGATIONAL NEW DRUGS (2013)
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
Arnaud Jaccard et al.
BLOOD (2011)
Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
Motoko Yamaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Wing-yan Au et al.
BLOOD (2009)
Share Paper
